Shares of Taser International, the US company that makes stun guns, have tumbled in New York after it warned that sales would miss analyst targets.
Life saver or death risk?
It blamed the dip on concerns about the safety of its products and criticism from human rights group Amnesty.
Taser called the allegations "erroneous and misleading".
Shares fell 13% to $10.42 after it said sales would be $10m (£5.3m) in the three months ending 31 March - the market expected a figure close to $14m.
Taser's stock has lost more than 60% of its value in the first quarter of this year, wiping $1.4bn off its market value.
"Significant adverse publicity in the first quarter has caused what we believe to be a temporary disruption in our sales pipeline," said Taser chief executive Rick Smith.
Mr Smith went on to say that a number of reports carried out by agencies including the UK Home Office showed that Taser products, "while not risk free, are generally safe".
Taser have been trialled and welcomed by police forces across the world, many of which have been looking for a weapon that is less lethal than a firearm.
Amnesty has called for the stun guns, which administer a high voltage shock of electricity that incapacitates a person, to be treated as "potentially lethal weapons".
The lobby group says that Taser guns have been linked to 70 deaths in the US and should only be used in extreme cases.
"We are disheartened at Amnesty's rhetoric and continued misrepresentation of the facts regarding Taser devices," Mr Smith said.
The company said on Wednesday that an independent study had found its guns are "relatively safe".
However, in its report the Potomac Institute added that it "strongly recommends that additional research be conducted at the organism, organ, tissue, and cell levels" so it could better understand the effects of the stun guns.